10 results on '"Barkat Khan"'
Search Results
2. Technologies for Solubility, Dissolution and Permeation Enhancement of Natural Compounds
- Author
-
Ahmad Salawi, Barkat Khan, Meshal Alshamrani, Yosif Almoshari, and Muhammad Khalid Khan
- Subjects
Drug Discovery ,Pharmaceutical Science ,Molecular Medicine - Abstract
The current review is based on the advancements in the field of natural therapeutic agents which could be utilized for a variety of biomedical applications and against various diseases and ailments. In addition, several obstacles have to be circumvented to achieve the desired therapeutic effectiveness, among which limited dissolution and/or solubility and permeability are included. To counteract these issues, several advancements in the field of natural therapeutic substances needed to be addressed. Therefore, in this review, the possible techniques for the dissolution/solubility and permeability improvements have been addressed which could enhance the dissolution and permeability up to several times. In addition, the conventional and modern isolation and purification techniques have been emphasized to achieve the isolation and purification of single or multiple therapeutic constituents with convenience and smarter approaches. Moreover, a brief overview of advanced natural compounds with multiple therapeutic effectiveness have also been anticipated. In brief, enough advancements have been carried out to achieve safe, effective and economic use of natural medicinal agents with improved stability, handling and storage.
- Published
- 2022
3. Dynamic changes of the composition of plasma HDL particles in patients with cardiac disease: Spotlight on sphingosine-1-phosphate/serum amyloid A ratio
- Author
-
Yassine El Hiani, Vincent Maher, Rebecca Canning, Rebabonye B. Pharithi, Emmanuel E. Egom, Haaris A. Shiwani, and Barkat Khan
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Heart Diseases ,Physiology ,Inflammation ,030204 cardiovascular system & hematology ,medicine.disease_cause ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,High-density lipoprotein ,Sphingosine ,Physiology (medical) ,Internal medicine ,medicine ,Humans ,Sphingosine-1-phosphate ,Serum amyloid A ,Pharmacology ,Serum Amyloid A Protein ,Cholesterol ,business.industry ,Cholesterol, HDL ,Acute-phase protein ,030104 developmental biology ,Endocrinology ,chemistry ,lipids (amino acids, peptides, and proteins) ,Lysophospholipids ,medicine.symptom ,business ,Oxidative stress ,Lipoprotein - Abstract
Several epidemiological studies reported an inverse relationship between plasma high-density lipoprotein (HDL) cholesterol levels and atherosclerotic cardiovascular disease (ASCVD). However, therapeutic interventions targeted at raising HDL-cholesterol failed to improve cardiovascular outcomes, suggesting that HDL components distinct from cholesterol may account for the anti-atherothrombotic effects attributed to this lipoprotein. Sphingosine-1-phosphate (S1P) and the acute phase protein serum amyloid A (SAA) have been identified as integral constituents of HDL particles. Evidence suggests that S1P and SAA levels within HDL particles may be affected by inflammation and oxidative stress, which are coexisting processes underlying ASCVD. Because SAA, an inflammation-related marker, and S1P, an anti-atherothrombotic marker, have relatively clear opposite characteristics among the HDL-associated proteins, the approach of assessing the two markers simultaneously may provide new insights in clinical practice (S1P/SAA Index). This review focuses on evidence in support of the concept that the S1P/SAA Index may affect the HDL atheroprotective properties and may, therefore represent a potential target for therapeutic interventions.
- Published
- 2017
4. Time to redefine body mass index categories in chronic diseases? Spotlight on obesity paradox
- Author
-
Peter Kruzliak, Yassine El-Hiani, Barkat Khan, Vincent Maher, Emmanuel E. Egom, Haaris A. Shiwani, and Rebabonye B. Pharithi
- Subjects
Gerontology ,medicine.medical_specialty ,Disease ,030204 cardiovascular system & hematology ,Overweight ,Body Mass Index ,03 medical and health sciences ,Human health ,0302 clinical medicine ,Risk Factors ,Epidemiology ,medicine ,Humans ,Obesity ,030212 general & internal medicine ,2. Zero hunger ,business.industry ,Public health ,medicine.disease ,Survival Analysis ,3. Good health ,Body Composition ,medicine.symptom ,business ,Body mass index ,Obesity paradox ,Food Science - Abstract
Obesity is a complex condition classically characterised by excessive body fat accumulation and represents one of the most important public health problems worldwide. Although several epidemiological studies have shown that elevated BMI is associated with higher morbidity, and with increased rate of death from all causes and from cardiovascular disease, accumulating evidence suggests that being overweight or obese may be protective (the so-called obesity paradox), at least in chronic diseases. These observations, not only question the validity of the BMI system, but also raise the intriguing question of whether we should redefine what the normal range of BMI is in individuals suffering from a chronic disease. In the present article, we review the available information on the association between elevated BMI and increased morbidity and mortality including obesity-related paradoxes, explore key aspects of the role and limitations of BMI as a measure of increased adiposity and outline potential solutions to address the current controversies regarding the impact of obesity on human health.
- Published
- 2017
5. A natriuretic peptides clearance receptor’s agonist reduces pulmonary artery pressures and enhances cardiac performance in preclinical models: New hope for patients with pulmonary hypertension due to left ventricular heart failure
- Author
-
Hilaire A. Ribama, Emmanuel E. Egom, Haaris A. Shiwani, Rebabonye B. Pharithi, Tiam Feridooni, Yassine El Hiani, Barkat Khan, Vincent Maher, and Kishore B.S. Pasumarthi
- Subjects
Male ,0301 basic medicine ,Agonist ,medicine.medical_specialty ,medicine.drug_class ,Heart Ventricles ,Hypertension, Pulmonary ,Pulmonary Artery ,030204 cardiovascular system & hematology ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Atrial natriuretic peptide ,Heart Rate ,medicine.artery ,Internal medicine ,Pressure ,medicine ,Animals ,Natriuretic Peptides ,Receptor ,Lung ,Heart Failure ,Pharmacology ,Medical treatment ,business.industry ,General Medicine ,medicine.disease ,Pulmonary hypertension ,Pathophysiology ,030104 developmental biology ,Heart failure ,Pulmonary artery ,Cardiology ,business ,Receptors, Atrial Natriuretic Factor ,Atrial Natriuretic Factor - Abstract
In patients with left ventricular heart failure (HF), the development of pulmonary hypertension (PH) is common and represents a strong predictor of death. Despite recent advances in the pathophysiological understanding there is as yet no prospect of cure of this deadly clinical entity and the majority of patients continue to progress to right ventricular failure and die. Furthermore, there is no single medical treatment currently approved for PH related to HF. There is, therefore an urgent unmet need to identify novel pharmacological agents that will prevent the progressive increased or reverse the elevated pulmonary arterial pressures while enhancing cardiac performance in HF.We here reported, for the first time, using a pressure-loop (P-V) conductance catheter system, that a specific natriuretic peptides clearance receptors' agonist, the ring-deleted atrial natriuretic peptide analogue, cANF4-23 (cANF) reduces pulmonary artery pressures. Strikingly, the administration of the cANF in these mice decreased the RVSP by 50% (n=5, F 25.687, DF 14, p0.001) and heart rate (HR) by 11% (n=5, F 25.69, DF 14, p0.001) as well as enhancing cardiac performance including left ventricular contractility in mice. Most strikingly, mice lacking NPR-C were much more susceptible to develop HF, indicating that NPR-C is a critical protective receptor in the heart.Natriuretic peptides clearance receptors' agonists may, therefore represent a novel and attractive therapeutic strategy for PH related to HF, and ultimately improves the life expectancy and quality for millions of people around the planet.
- Published
- 2017
6. Latest Updates on Lipid Management
- Author
-
Martin Caprnda, Emmanuel E. Egom, Ioana Mozos, Neasa Starr, Vincent Maher, Richard Armstrong, Peter Kubatka, Rebabonye B. Pharithi, Ludovit Gaspar, Katarina Gazdikova, Peter Kruzliak, Habitha Mohammed Sulaiman, Barkat Khan, and Soressa Hesse
- Subjects
0301 basic medicine ,medicine.medical_specialty ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Pharmacotherapy ,Risk Factors ,Internal Medicine ,Medicine ,Humans ,Intensive care medicine ,Exercise ,Triglycerides ,Cause of death ,Dyslipidemias ,Secondary prevention ,Lipid management ,business.industry ,Cholesterol ,Atherosclerotic cardiovascular disease ,Anticholesteremic Agents ,Protective Factors ,Atherosclerosis ,030104 developmental biology ,Treatment Outcome ,chemistry ,lipids (amino acids, peptides, and proteins) ,Diet, Healthy ,Cardiology and Cardiovascular Medicine ,business ,Risk Reduction Behavior ,030217 neurology & neurosurgery ,Biomarkers - Abstract
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death worldwide. Despite the clinical long-term and near-term benefits of lowering cholesterol in, respectively, primary and secondary prevention of ASCVD, cholesterol levels remain under-treated, with many patients not achieving their recommended targets. The present article will review the latest updates on lipid management with emphases on the different classes of cholesterol-lowering agents and their clinical uses.
- Published
- 2018
7. Erratum: New insights and new hope for pulmonary arterial hypertension: natriuretic peptides clearance receptor as a novel therapeutic target for a complex disease
- Author
-
Emmanuel Eroume-A, Egom, Tiam, Feridooni, Rebabonye B, Pharithi, Barkat, Khan, Haaris A, Shiwani, Vincent, Maher, Yassine, El Hiani, Robert A, Rose, Kishore Bs, Pasumarthi, and Hilaire A, Ribama
- Subjects
Original Article - Abstract
Background: Pulmonary Arterial Hypertension (PAH) is a deadly and disabling disease for which there is no marketed drug that addresses the underlying disease mechanism and targets to cure patients. The lack of understanding of the disease mechanism represents the main challenges in developing curative therapies. We here report, for the first time, that mice lacking natriuretic peptides clearance receptor develop PAH. Methods and Results: Initial studies assessed cardiac structure and function in NPR-C+/+ (wild type) and age matched, littermate NPR-C-/- mice by echocardiography. Mice lacking NPR-C had right atrial dilation, tricuspid regurgitation as well as echocardiographic signs of right ventricular pressure overload, including flattening and paradoxical bulging of the septum into the left ventricle during systole, and hypertrophy of the right ventricular free wall. Among the 10 NPR-C-/- mice aged between 12 and 20 weeks studied, 8 showed the above typical echocardiographic features of PAH [80%, 95% CI: (0.4439-0.9748)], and only one had pericardial effusion [10%, 95% CI: (0.0025-0.4450)], finding that has a prognostic significance in subjects affected by this clinical entity. To confirm the presence of increased right ventricular systolic pressure (RVSP) among NPR-C-/- mice, right heart catheterization was performed. Strikingly, RVSP was significantly elevated in NPR-C-/- mice compared to their age matched, littermate NPR-C+/+ mice, at baseline (21.95±0.56 mmHg vs. 5.3±0.6 mmHg, respectively (P
- Published
- 2017
8. Discharge planning in a cardiology out-patient clinic: a clinical audit
- Author
-
Barkat Khan and Shirley Ingram
- Subjects
Clinical audit ,medicine.medical_specialty ,Quality Assurance, Health Care ,Cardiology ,MEDLINE ,Audit ,Efficiency, Organizational ,Ambulatory Care Facilities ,Clinical nurse specialist ,Internal medicine ,Health care ,medicine ,Humans ,Quality Indicators, Health Care ,Clinical Audit ,business.industry ,Health Policy ,Medical record ,Attendance ,General Business, Management and Accounting ,Patient Discharge ,Discharge planning ,Emergency medicine ,Nurse Clinicians ,business - Abstract
Purpose – The purpose of this paper is to audit the active discharge (DC) planning process in a general cardiology clinic, by pre-assessing patients’ medical notes and highlighting those suitable for potential DC to the clinic physician. Design/methodology/approach – The cardiology clinical nurse specialist (CNS) identified patients’ for nine- to 12-month return visits one week prior to attendance. The previous consultation letter was accessed and information was documented by the CNS in the medical record. The key performance indicator (KPI) used was patient DCs for each clinic visit. The process was audited at three separate times to reflect recommended action carried out. Findings – The CNS pre-assessment and presence at the clinics significantly increased total DCs during the first period compared to usual care, 11 vs 34 per cent (p Practical implications – CNS pre-assessment and highlighting DC suitability increased the number of patient DCs. As the CNS presence at the clinic reduced so did the rate of DC. Specific personnel need to be responsible for monitoring and reminding staff of the process; this does not always have to be medical or nursing. Originality/value – Implementing positive discharging procedures is aimed at improving quality, increasing efficiency and accessibility of services for patients. This audit describes a process to promote DC planning from cardiology outpatients.
- Published
- 2014
9. Fabrication of anti-vitiligo ointment containing
- Author
-
Irshad, Hussain, Nisar, Hussain, Abdul, Manan, Abdur, Rashid, Barkat, Khan, and Sattar, Bakhsh
- Subjects
Ointments ,vitiligo ,leucoderma ,Humans ,PC ,Candidiasis, Cutaneous ,anti-vitiligo ointment ,novel design optimization ,babchi ,Psoralea corylifolia ,Original Research ,puva ,Psoralea - Abstract
Background Vitiligo is a repugnant and odious dermatological malady of the time. It has an detrimental impact on the pigmentation of the human skin as a result of the destruction of cutaneous melanocytes. It affects 1%–2% of the population worldwide. Different therapeutic regimens have been deployed to treat vitiligo, but none of them could stand alone to be stated as a perfect cure. Recently, a change has been observed through novel experimental-designed optimization leading to the development of an anti-vitiligo ointment containing Psoralea corylifolia (PC) seed powder. Aim The aim of this study was to explore the clinical outcomes of ointment containing powdered seeds of PC. Materials and methods Guided by the protocol Response Surface Methodology, 13 formulations of concentration variance of permeation enhancers were prepared. The formulation fulfilling the required criteria (pH; temperature stability tests at 8°C±0.1°C, 25°C±0.1°C and 40°C±0.1°C; and the physical properties such as color, bleeding and rheology) was selected for clinical trials. Fourier transform infrared spectroscopy studies of seed powder of PC and selected formulation of the seed powder were performed. After obtaining informed consents and with prior approval of university and hospital ethical review boards, 20 patients (age range 25–65 years) were included in the present study. Formulations were applied on the affected body parts of patients, and some affected portion of the same patient was taken as control (self-control study design). The pigmentation of white spots of vitiligo was photographically evaluated before, during and after 12 weeks of treatment. Analysis of the measured values was performed using GraphPad Prism version 5 statistical software. A paired sample t-test was performed to observe variation between repigmented patches and white patches of self-control. Results Hydrophilic ointment (10% w/w) prepared with seed powder of PC was fabricated. The ointment was found effective for small circular white lesions of vitiligo as compared to self-control. Pre- and post-treatment differences in the levels of pigmentation were statistically significant (P≤0.05). Conclusion Ointment containing seed powder of PC could be an effective monotherapy for small circular white lesions of vitiligo.
- Published
- 2016
10. An update on the 2014 Ebola outbreak in western Africa
- Author
-
Peter Kruzliak, Christian Binoun A. Egom, Emmanuel E. Egom, Haaris A. Shiwani, Rebabonye B. Pharithi, Vincent Maher, and Barkat Khan
- Subjects
0301 basic medicine ,Medicine(all) ,Economic growth ,Ebola virus ,Transmission (medicine) ,business.industry ,Disease recovery ,Outbreak ,General Medicine ,Disease ,medicine.disease_cause ,Virology ,3. Good health ,Vaccination ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,medicine ,030212 general & internal medicine ,business - Abstract
The recent Ebola outbreak in Western Africa was the most devastating outbreak witnessed in recent times. There have been remarkable local and international efforts to control the crisis. Ebola Virus Disease is the focus of immense research activity. The progression of events in the region has been evolving swiftly and it is of paramount importance to the medical community to be acquainted with the situation. Over 28000 people were inflicted with the condition, over 11000 have died. Novel data has emerged regarding modes of transmission, providing rationale for recent flare-ups. Similarly, studies on survivors are elucidating the later stages of the disease recovery process. Novel techniques for diagnosis are also discussed. Finally, the current research regarding treatment and vaccine development is reviewed, particularly the implementation of rVSV-ZEBOV vaccination programs.
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.